– Funding will Advance Development of Ray Therapeutics’ Optogenetics Technology Platform – Company will Advance Ray-001 for the Treatment of Retinitis Pigmentosa –

Posted on March 1, 2022 (March 1, 2022) by Forge Biologics SAN DIEGO, CALIFORNIA AND COLUMBUS, OHIO March 1, 2022 – Ray Therapeutics, a biotechnology company developing optogenetic gene therapies

Top-tier advanced therapies investor 4BIO Capital led the financing round.

The financing will be used to advance its lead optogenetics gene therapy Ray-001 into clinical trials for retinitis pigmentosa.